Ayvakit
Active Ingredient(s): AvapritinibFDA Approved: * January 9, 2020
Pharm Company: * BLUEPRINT MEDICINES
Category: Cancer
Avapritinib, sold under the brand name Ayvakit among others, is a medication used for the treatment of advanced systemic mastocytosis and for the treatment of tumors due to one specific rare mutation: it is specifically intended for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) that harbor a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation.[1][3] Common side effects include edema (swelling), nausea, fatigue/... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.